Moberg Pharma and Karo Healthcare Forge Exclusive Licensing Deal for Terclara Across Europe

Strategic Licensing Agreement: Moberg Pharma & Karo Healthcare

In a significant development for the European pharmaceutical market, Moberg Pharma AB has announced an exclusive licensing agreement with Karo Healthcare AB. This deal centers on the marketing of MOB-015, branded as Terclara, across 19 European nations. This step not only underscores the increasing demand for innovative treatments but also broadens the accessibility of MOB-015 to approximately 500 million people in major EU markets, including the United Kingdom.

Expansion into Key Markets

The agreement allows Moberg to leverage Karo Healthcare's established presence in Europe to ensure a coherent launch strategy in crucial markets. Karo will be at the forefront of distribution, marketing, and sales, effectively utilizing their resources and expertise to optimize the reach of the Turbinafine-based product. While specific financial details remain undisclosed, the partnership involves various compensations aligned with product delivery and sales royalties.

Anna Ljung, CEO of Moberg Pharma, expressed enthusiasm for this collaboration, highlighting the potential for MOB-015 to emerge as a market leader beyond its current presence in Sweden and Norway. Karo Healthcare's robust commercial network, known for its strength across Europe, offers Moberg Pharma a competitive edge needed to thrive in this dynamic market.

Terclara: A New Standard in Treatment

MOB-015, or Terclara, represents the new frontier in antifungal therapies, especially for conditions like nail fungus and athlete's foot. Historically, patients have faced challenges with oral treatments, which carry risks of adverse side effects, including liver damage and drug interactions. Terclara, however, offers a topical solution that diminishes these risks.

Moberg's innovative approach has resulted in a topical formulation capable of achieving metrics comparable to those of traditional oral therapies. In clinical registration studies, 76% of participants reported a mycological cure, illustrating Terclara's effectiveness. This recent breakthrough underscores why launching Terclara under the renowned Lamisil brand—a name synonymous with antifungal efficacy—amplifies its market potential.

Next Steps for Launch

While the use of the Lamisil name is a strategic advantage, the implementation hinges on gaining necessary approvals from various national health authorities across Europe. As both companies work to expedite the launch process, it is expected that the first waves of Terclara will hit the market soon. Moreover, they plan to extend its marketing authorizations to additional countries, initially prioritizing those markets that have already given their approval.

The Role of Karo Healthcare

Karo Healthcare, recognized as a significant player in the European healthcare landscape, brings indispensable expertise and established distribution channels, which significantly reduce the time required to launch Terclara effectively. With a backing from global investment firm KKR and an ambitious expansion strategy, Karo is well-poised to transition products from prescription to non-prescription markets.

Despite Moberg Pharma's withdrawal from direct launch initiatives in Europe, the company anticipates maintaining a crucial role in commercial operations outside of Europe, specifically in the U.S. market, aligning with their long-term growth vision.

Conclusion

This agreement marks a pivotal milestone for both Moberg Pharma and Karo Healthcare, solidifying their positions in the evolving landscape of pharmaceutical treatments for fungal infections. The future of MOB-015/Terclara appears bright as the partnership aims to set a new standard in efficacy, safety, and accessibility for patients across Europe.

For further information, Moberg Pharma has made it clear that they remain committed to reinforcing their research and development to continue providing solutions that meet patient needs and preferences. This partnership not only signifies growth but also serves as an innovative response to market demands in the healthcare sector.